Zardaverine

Last updated
Zardaverine
Zardaverine.svg
Names
IUPAC name
3-[4-(Difluoromethoxy)-3-methoxyphenyl]-1H-pyridazin-6-one
Identifiers
3D model (JSmol)
ChemSpider
PubChem CID
UNII
  • InChI=1S/C12H10F2N2O3/c1-18-10-6-7(2-4-9(10)19-12(13)14)8-3-5-11(17)16-15-8/h2-6,12H,1H3,(H,16,17)
    Key: HJMQDJPMQIHLPB-UHFFFAOYSA-N
  • COC1=C(C=CC(=C1)C2=NNC(=O)C=C2)OC(F)F
Properties
C12H10F2N2O3
Molar mass 268.220 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Zardaverine is a dual-selective PDE3/4 phosphodiesterase inhibitor. [1] Studies in vitro suggest that it may have useful anti-cancer properties. [2]

References

  1. ↑ Kümmerle, AE; Schmitt, M; Cardozo, SV; Lugnier, C; Villa, P; Lopes, AB; Romeiro, NC; Justiniano, H; Martins, MA; Fraga, CA; Bourguignon, JJ; Barreiro, EJ (2012). "Design, Synthesis, and Pharmacological Evaluation of N-Acylhydrazones and Novel Conformationally Constrained Compounds as Selective and Potent Orally Active Phosphodiesterase-4 Inhibitors". Journal of Medicinal Chemistry. 55 (17): 7525–45. doi:10.1021/jm300514y. PMID   22891752.
  2. ↑ Corsello, SM; Nagari, RT; Spangler, RD; Rossen, J; Kocak, M; Bryan, JG; Humeidi, R; Peck, D; Wu, X; Tang, AA; Wang, VM; Bender, SA; Lemire, E; Narayan, R; Montgomery, P; Ben-David, U; Garvie, CW; Chen, Y; Rees, MG; Lyons, NJ; McFarland, JM; Wong, BT; Wang, L; Dumont, N; o'Hearn, PJ; Stefan, E; Doench, JG; Harrington, CN; Greulich, H; Meyerson, M (2020). "Discovering the anticancer potential of non-oncology drugs by systematic viability profiling". Nature Cancer. 1 (2): 235–248. doi:10.1038/s43018-019-0018-6. PMC   7328899 . PMID   32613204.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.